2345-34-8Relevant articles and documents
Padilla,Herran
, p. 427,431 (1962)
Morgan,Orsler
, p. 1007,1012 (1967)
Discovery of β-Adrenergic Receptors Blocker-Carbonic Anhydrase Inhibitor Hybrids for Multitargeted Antiglaucoma Therapy
Nocentini, Alessio,Ceruso, Mariangela,Bua, Silvia,Lomelino, Carrie L.,Andring, Jacob T.,McKenna, Robert,Lanzi, Cecilia,Sgambellone, Silvia,Pecori, Riccardo,Matucci, Rosanna,Filippi, Luca,Gratteri, Paola,Carta, Fabrizio,Masini, Emanuela,Selleri, Silvia,Supuran, Claudiu T.
, p. 5380 - 5394 (2018)
The combination of a β-adrenergic receptors (AR) blocker and a carbonic anhydrase (CA, EC 4.2.1.1) inhibitor in eye drops formulations is one of the most clinically used treatment for glaucoma. A novel approach consisting of single-molecule, multitargeted compounds for the treatment of glaucoma is proposed here by designing compounds which concomitantly interact with the β-adrenergic and CA targets. Most derivatives of the two series of benzenesulfonamides incorporating 2-hydroxypropylamine moieties reported here exhibited striking efficacy against the target hCA II and XII, whereas a subset of compounds also showed significant modulation of β1- and β2-ARs. X-ray crystallography studies provided rationale for the observed hCA inhibition. The best dual-agents decreased IOP more effectively than clinically used dorzolamide, timolol, and the combination of them in an animal model of glaucoma. The reported evidence supports the proof-of-concept of β-ARs blocker-CAI hybrids for antiglaucoma therapy with an innovative mechanism of action.
Identification of Novel Resorcinol Amide Derivatives as Potent and Specific Pyruvate Dehydrogenase Kinase (PDHK) Inhibitors
Cho, Hanna,Cho, Kyungseon,Kim, Mi-Jin,Kim, Nam Doo,Lee, In-Kyu,Park, Sungmi,Shin, Injae,Sim, Taebo,Yoo, Eun Kyung,Yoon, Hojong
, (2019)
Pyruvate dehydrogenase kinases (PDHKs) promote abnormal respiration in cancer cells. Studies with novel resorcinol amide derivatives based on VER-246608 (6) led to the identification of 19n and 19t containing five-membered heteroaromatic rings as unique structural features. These substances possess single-digit nanomolar activities against PDHKs. 19t exhibits higher potencies against PDHK1/2/4 than does 6 and inhibits only PDHKs among 366 kinases. Moreover, 19g, 19l, and 19s were found to be isotype-selective PDHK inhibitors. Molecular dynamics simulations provide a better understanding of how the heteroaromatic rings affect the activities of 19n and 19t on PDHK1/2/3/4. Moreover, 19n possesses a much higher antiproliferative activity against cancer cells than does 6. We demonstrated that the results of PDH assays better correlate with cellular activities than do those of PDHK kinase assays. Furthermore, 19n induces apoptosis of cancer cells via mitochondrial dysfunction, suppresses tumorigenesis, and displays a synergistic effect on satraplatin suppression of cancer cell proliferation.
Aryl alkyl ether compound as well as derivative, preparation method, pharmaceutical composition and application thereof
-
Paragraph 0261; 0262; 0265; 0266, (2021/05/12)
The invention discloses an aryl alkyl ether compound as well as a derivative, a preparation method, a pharmaceutical composition and application thereof. The structure of the aryl alkyl ether compound is shown as a formula (I). The aryl alkyl ether compound derivative relates to a stereoisomer, a tautomer, a metabolite, a metabolic precursor, a prodrug, a solvate, a salt of the solvate, a crystal, a pharmaceutically acceptable salt or a mixture of the stereoisomer, the tautomer, the metabolite, the metabolic precursor, the prodrug and the solvate of the aryl alkyl ether compound. The aryl alkyl ether compound and the derivative thereof have a remarkable inhibition effect on indoleamine 2, 3-dioxygenase 1, and can be used for preparing a medicine for treating indoleamine 2, 3-dioxygenase 1 mediated immunosuppression related diseases, and the prepared medicine can exert the medicine effect at the molecular level and is wide in application.
PROCESSES FOR PREPARING AN S1P-RECEPTOR MODULATOR
-
Page/Page column 33, (2021/05/07)
This application relates to processes for preparing an S1P-receptor modulator "Compound 1", which is useful in the treatment of diseases or disorders associated with activity of S1P, including CNS disorders. The process comprises reacting "compound 2" with "compound 3" in the presence of a reducing agent.